Stockscreener 앱 받기
1.11
0.91%
0.01
시간 외 거래:
1.11
Humacyte Inc 주식(HUMA)의 최신 뉴스
Whale Trades: Whats the fair value of Humacyte Inc stock2025 Price Momentum & Daily Volume Surge Trade Alerts - baoquankhu1.vn
Humacyte, Inc. (HUMA) Stock Analysis: Exploring a Potential 614% Upside in the Biotech Sector - DirectorsTalk Interviews
Published on: 2026-01-15 08:53:32 - baoquankhu1.vn
Analyst Upgrade: Can Humacyte Inc. stock maintain growth trajectoryTrade Signal Summary & Weekly Momentum Picks - Bộ Nội Vụ
CEO Moves: What catalysts could drive Humacyte Inc. stock higherPortfolio Risk Report & Fast Gain Stock Tips - Bộ Nội Vụ
Humacyte, Inc. (NASDAQ:HUMA): Are Analysts Optimistic? - Yahoo Finance
Quarterly Risk: Does Humacyte Inc Equity Warrant stock benefit from AI growthPortfolio Return Report & Verified Swing Trading Watchlists - baoquankhu1.vn
While institutions invested in Humacyte, Inc. (NASDAQ:HUMA) benefited from last week's 10% gain, retail investors stood to gain the most - simplywall.st
Wall Street analysts see Humacyte, Inc. (HUMA) as a buy: Should you invest? - MSN
Is Humacyte Inc. Equity Warrant stock undervalued vs historical averagesTrail vs Road Selection & quick comparison of popular models - ulpravda.ru
How buybacks impact Humacyte Inc. Equity Warrant stock valueJuly 2025 Gainers & Entry Point Confirmation Alerts - ulpravda.ru
Will Humacyte Inc. Equity Warrant stock gain from lower inflationPortfolio Gains Report & Fast Gaining Stock Reports - ulpravda.ru
Humacyte, Inc. (HUMA) Stock Analysis: Unveiling a Potential 571.55% Upside in the Biotech Sector - DirectorsTalk Interviews
Is Humacyte Inc. Equity Warrant stock a contrarian buyQuarterly Growth Report & Real-Time Volume Spike Alerts - ulpravda.ru
Will Humacyte Inc. stock recover faster than peersJuly 2025 Movers & Reliable Intraday Trade Alerts - ulpravda.ru
Can Humacyte Inc. Equity Warrant stock resist market sell offsOptions Play & Fast Gain Swing Trade Alerts - ulpravda.ru
Winners Losers: Can Humacyte Inc. stock deliver sustainable ROE2025 Sector Review & AI Enhanced Trading Alerts - ulpravda.ru
Form 8-KCurrent report - ADVFN
What sentiment indicators say about Humacyte Inc. stockMarket Sentiment Report & Weekly High Return Stock Opportunities - ulpravda.ru
Can Humacyte Inc. stock sustain revenue growthJuly 2025 Volume & Verified Chart Pattern Trade Signals - ulpravda.ru
How strong is Humacyte Inc. Equity Warrant stock revenue growthMarket Performance Report & Precise Buy Zone Identification - ulpravda.ru
Can Humacyte Inc. stock deliver sustainable ROEQuarterly Market Summary & AI Driven Stock Reports - ulpravda.ru
Today's Analyst Ratings: Humacyte (HUMA) Maintains "Buy" Rating - GuruFocus
Humacyte enters sales agreement with TD Securities - MSN
Preventable surgery complications can drive hospital charges toward $600K - Stock Titan
Humacyte Announces Hospital Charge Data Showing High Expense of Preventable Extremity Arterial Injury Complications - Yahoo Finance
Patterns Watch: Can Humacyte Inc stock deliver sustainable ROESwing Trade & Risk Managed Investment Signals - moha.gov.vn
Humacyte, Inc.Common Stock (NQ: HUMA - FinancialContent
Is Humacyte, Inc. (HUMA) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Form 10-QQuarterly report [Sections 13 or 15(d)] - ADVFN
Humacyte rises on Symvess sale to military treatment facility - MSN
Humacyte jumps as DoD issues ECAT listing approval for Symvess - MSN
Humacyte Announces Planned Marketing Authorization Application for Symvess in Israel - marketscreener.com
Humacyte Inc announces planned marketing authorization application for Symvess in Israël - marketscreener.com
D. Boral Capital Reiterates "Buy" Rating for Humacyte (NASDAQ:HUMA) - MarketBeat
Humacyte plans to seek approval for vessel product in Israel - Investing.com
Humacyte plans to seek approval for vessel product in Israel By Investing.com - Investing.com South Africa
Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel - The Manila Times
Humacyte, Inc. (HUMA) Stock Analysis: Exploring A Potential 718% Upside In Biotechnology - DirectorsTalk Interviews
Rate Hike: Is Humacyte Inc stock attractive for income investorsDollar Strength & Daily Entry Point Trade Alerts - moha.gov.vn
Humacyte, Inc. (NASDAQ:HUMA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Why Is Humacyte, Inc. (HUMAW) Stock Down Today? - Meyka
Can Humacyte Inc. Equity Warrant stock maintain growth trajectoryChart Pattern Recognition & Compound Your Gains With Quality Stocks - Bollywood Helpline
Humacyte's (HUMA) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
Humacyte Reports High Limb Salvage Rates and Durability of Symvess in Long-Term Study Published in JVS-CIT - Quiver Quantitative
Off-the-shelf blood vessel implant helps save injured limbs in study - Stock Titan
Humacyte announces credit facility of $77.5M with Avenue Capital - MSN
Regulatory Ruptures For A Lab-Grown Blood Vessel - The Lever
Humacyte terminates revenue interest agreement - MSN
Humacyte (NASDAQ:HUMA) Stock Rating Lowered by Wall Street Zen - MarketBeat
Is Humacyte Inc. stock attractive for income investorsEarnings Risk Summary & Detailed Earnings Play Strategies - DonanımHaber
Can Humacyte Inc. stock surprise with earnings upsideWeekly Trade Summary & High Accuracy Investment Entry Signals - bolumsonucanavari.com
What catalysts could drive Humacyte Inc. Equity Warrant stock higher2025 Market Outlook & Real-Time Volume Trigger Notifications - DonanımHaber
Humacyte, Inc. (HUMA) Stock Analysis: Biotechnology Visionary with a 607.85% Potential Upside - DirectorsTalk Interviews
Can Humacyte Inc. Equity Warrant stock beat market expectations this quarterQuarterly Growth Report & Daily Profit Maximizing Trade Tips - ulpravda.ru
Published on: 2025-12-19 01:36:49 - Улправда
Is Humacyte Inc. Equity Warrant stock affected by interest rate hikesCEO Change & Reliable Breakout Forecasts - Улправда
4.73%
0.92%
자본화:
|
볼륨(24시간):